Public Market Pivot LivsMed is advancing toward an IPO on the KOSDAQ, signaling increased capital and growth capacity. This creates potential for strategic partnerships and investor-aligned collaborations, especially with distributors and OEMs seeking scaled manufacturing and global reach.

Global Distribution Existing distribution partnerships in China and Singapore and plans for international expansion suggest opportunities to engage regional distributors and hospital networks that need ArtiSential line integration, training, and localized support.

ArtiSential Advantage The ArtiSential 5 and 90° articulating vessel sealer innovations position LivsMed as a supplier of advanced minimally invasive tools. Target hospitals upgrading tech stacks or expanding laparoscopic programs may see strong value in adding these hardware solutions to their suites.

Private-Public Readiness With revenues in the mid tens of millions and a clear market expansion trajectory, there is opportunity to pitch bundled offerings such as training, service contracts, and installation support to large health systems and ambulatory surgery centers seeking reliable instrument ecosystems.

Clinical Collaboration New product launches and conference presence indicate readiness for clinical partnerships. Propose joint research, clinical studies, and surgeon-led trials with hospitals to demonstrate outcomes and accelerate adoption of ArtiSential tools.